Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of bortezomib plus pegylated liposomal doxorubicin in BRCA wild-type platinum-resistant recurrent ovarian cancer
KCT0003266Phase 2Completed
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- May 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, doxorubicin in ovarian cancer, sponsored by Samyang Biopharmaceuticals Corporation. Started May 2018; status: completed.
02
Drugs
bortezomibdoxorubicin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on KCT0003266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003266.